Tocilizumab can boost catch-up growth in systemic JIA

11/14/2012 | Family Practice News

Tocilizumab, an interleukin-6 receptor inhibitor marketed as Actemra, significantly increased the height velocities of most patients with systemic juvenile idiopathic arthritis, according to a study presented at the American College of Rheumatology meeting. Higher insulinlike growth factor-1 levels and osteocalcin/C-telopeptide of type 1 collagen ratios linked to the use of the drug suggests the treatment can benefit growth hormone axis and bone metabolism, researchers said.

View Full Article in:

Family Practice News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC